by DNA repair drugs work by enhancing the body’s natural DNA repair mechanisms. They are able to identify and repair damaged DNA, preventing the formation of cancer-causing mutations. DNA repair is crucial for protecting cells from cancer-causing mutations that can lead to uncontrolled cell division and tumor growth. Key DNA repair drugs target DNA repair pathways such as base excision repair, nucleotide excision repair, mismatch repair, and direct reversal of damage. These drugs help repair single-strand and double-strand breaks as well as base damage in DNA caused by environmental exposures like UV radiation and chemicals or errors during DNA replication.
The global DNA Repair Drugs Market is estimated to be valued at US$ 7.24 Mn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the Global DNA Repair Drugs Market Size is the increasing focus on combination therapies. Combining DNA repair drugs with chemotherapy or other targeted therapies is emerging as a promising strategy for cancer treatment. This is because DNA repair inhibition can potentiate the anti-tumor activity of various cytotoxic agents. Olaparib (Lynparza), a PARP inhibitor, has shown efficacy as a maintenance monotherapy and in combination with chemotherapy for ovarian cancer. Other ongoing clinical trials are exploring DNA repair drug combinations with PD-1/PD-L1 inhibitors, CDK4/6 inhibitors, and radiotherapy for solid tumors. Combination strategies allow targeting of tumors through multiple mechanisms which can achieve better treatment outcomes compared to monotherapies. This focus on combination regimens is expected to drive market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: The DNA Repair Drugs Market requires a high level of Research and Development which creates high entry barriers for new players.
Bargaining power of buyers: Individual buyers have low bargaining power due to lack of alternative treatment options however pharmaceutical companies have moderately high bargaining power.
Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power due to lack of substitutes and established supply relationships of key players.
Threat of new substitutes: There is a low threat of substitutes currently as DNA repair drugs are relatively new and target damage at a molecular level.
Competitive rivalry: The market is highly competitive with major players like Accenture, Bristol-Myers Squibb focusing on expanding their product portfolio through partnerships and acquisitions.
Key Takeaways
The global DNA Repair Drugs Market is expected to witness high growth over the forecast period owing to rising geriatric population and increasing prevalence of cancer.
Regional analysis: North America is expected to dominate the global DNA Repair Drugs Market owing to increasing healthcare expenditure and presence of major players in the region. Moreover, Asia Pacific is anticipated to exhibit the fastest growth rate during the forecast period with growing biotech industry in China, Japan and India.
Key players: Key players operating in the DNA Repair Drugs Market are Accenture Plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc., GlaxoSmithKline, ICON, Plc, iGATE Corporation, Arriello, iMEDGlobal Corporation, Diamond Pharma Services, Infosys, Ergomed plc, inVentiv Health Inc., APCER Life Sciences, ArisGlobal, and Johnson and Johnson. Major players are focusing on strategic collaborative initiatives to gain higher market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
